Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genome-wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-treatment With 5-Azacytidine and Entinostat

Next Previous
Trial Profile

Genome-wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-treatment With 5-Azacytidine and Entinostat

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Entinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Pharmacogenomic

Most Recent Events

  • 17 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
  • 03 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
  • 11 Feb 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2015, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top